At a glance
- Originator Takeda
- Class Antineoplastics; Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 12 Jun 2000 No-Development-Reported for Cancer in Japan (Unknown route)
- 09 Dec 1998 New profile
- 09 Dec 1997 Preclinical development for Cancer in Japan (Unknown route)